Jasper Ridge Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Jasper Ridge Partners’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-92,939	Closed	-$148K	–	151
2023 Q1	$148K	Hold	92,939	–	–	0.01%	137
2022 Q4	$136K	Hold	92,939	–	–	0.01%	131
2022 Q3	$397K	Hold	92,939	–	–	0.03%	106
2022 Q2	$361K	Hold	92,939	–	–	0.02%	112
2022 Q1	$442K	Hold	92,939	–	–	0.02%	116
2021 Q4	$339K	Hold	92,939	–	–	0.01%	132
2021 Q3	$745K	Buy	+92,939	New	+$916K	0.03%	112

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jasper Ridge Partners's VIRX Position: Q2 2023 in Review

Jasper Ridge Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 92,939 shares — an estimated $148K sold.

Jasper Ridge Partners first reported a position in VIRX in Q3 2021 and held it in 7 quarters. The position peaked at $745K in Q3 2021. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

Jasper Ridge Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jasper Ridge Partners sold 92,939 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $148K.
Jasper Ridge Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Jasper Ridge Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $745K in Q3 2021.
41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Jasper Ridge Partners's 13F filing for Q2 2023, filed 14 Aug 2023.